Join us at the FSP 2023 Summer Pathology Conference taking place on July 14-16, 2023 at the Eau Palm Beach Resort & Spa.
The FSP 2023 Summer Pathology Conference will provide pathologists with education surrounding a wide range of topics and the opportunity to learn and adopt new strategies and tools to aid in the diagnosis and analysis of diseases. The conference will provide practical updates and clinical pearls and pitfalls in the following topics:
In addition, there will be education on additional topics during interactive read slides and microscopy sessions using an innovative digital platform. We are offering a new state mandated course on prevention of medical errors for pathologists on Friday, July 14 from 4:00 pm to 6:00 pm so make plans to join us early!
|Abstract Poster Submission #1|
|Disclosure of Funding Support|
|Choose one of the following Topics|
Justin Bishop, MD
Professor and Chief of Anatomic Pathology
UT Southwestern Medical Center
Topic: Head and Neck Pathology
Peter A. Humphrey, MD, PhD
Professor of Pathology
Director of Genitourinary Pathology
New Haven, CT
Topic: GU Pathology
Kamran M. Mirza, MD PhD
Vice-Chair of Education and Academic Affairs,
Program Director of Hematopathology fellowship,
Assistant Dean of DEI
Loyola University Chicago Stritch School of Medicine
Victor G. Prieto, MD, PhD
Univ of Texas – MD Anderson Cancer Center
Susan Boisvert BSN, MHSA, DFASHRM
Senior Patient Safety Risk Manager
The Doctors Company
Topic: Prevention of Medical Errors
12:15 pm – 1:00 pm
Signatera ctDNA Monitoring in the Management of Solid Tumors
Lunch will be served.
Michael Krainock, MD, PhD
Sponsored by Natera
5:45 pm - 6:30 pm
Unlocking the Future of Pathology: Integrating Digital Pathology and Molecular Profiling to Improve Patient Outcomes
Matthew J. Oberley, MD, PhD
Sponsored by Caris Life Sciences
The FSP 2023 Summer Pathology Conference will take place at the EAU Palm Beach.
Eau Palm Beach Resort & Spa
100 South Ocean Boulevard
Manalapan, Florida 33462
Visit Hotel Website
FSP attendees will receive a special room rate that starts at $319 per night, plus taxes. The group rate is guaranteed for reservations made on or before June 22, 2023 or until the room block is filled.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida Medical Association and the Florida Society of Pathologists. The Florida Medical Association is accredited by the ACCME to provide continuing medical education for physicians.
The Florida Medical Association designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CRITERIA FOR SUCCESS
Statements of credit/participation will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim credit form at www.flpath.org/claimcme . If you have questions about this CME/CE activity, please contact the FSP at 904-309-6261. Credit must be claimed by July 26, 2023.
This activity is designed to meet the needs of practicing physicians, pathologists, and other specialists involved with pathology.
STATEMENT OF NEED
The field of pathology is constantly changing, and many of the most important advances in the field. In the setting of new technology, techniques and advancements in the field, practice gaps are inevitable. As such, pathologists require ongoing educational opportunities to stay current in order to maintain and improve their knowledge and competence in the field.
At the conclusion of this activity, all participants should be able to:
COMMERCIAL SUPPORT AND EDUCATIONAL GRANTS
This activity is supported by an educational grant from AstraZeneca.
FACULTY AND PLANNER DISCLOSURES
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients except for Dr. Marilyn Bui who disclosed:
All of the relevant financial relationships listed for this individual have been mitigated (planner and moderator).
Justin Bishop, MD - Has nothing to disclose.
Kamran M. Mirza, MD PhD - Has nothing to disclose.
Susan Boisvert BSN, MHSA, DFASHRM - Has nothing to disclose.
Peter A. Humphrey, MD, PhD All of the relevant financial relationships listed for this individual have been mitigated.
Victor G. Prieto, MD, PhD All of the relevant financial relationships listed for this individual have been mitigated.
DISCLOSURE OF THE FLORIDA MEDICAL ASSOCIATION
It is the policy of the Florida Medical Association (FMA) to ensure independence, objectivity and scientific rigor in all approved CME content. CME faculty must present evidence-based data, clarify off-label product use and disclose all relevant financial relationships to the audience. The ideas and opinions expressed during jointly provided events do not necessarily reflect those of the FMA, and the FMA’s approval of course content for AMA PRA Category 1 Credits™. does not constitute an endorsement of the ideas, positions or statements contained therein. Every effort has been made to ensure that all information provided by the joint provider is accurate and current. However, FMA does not accept responsibility for errors or omissions and accepts no liability for any resulting loss or damage. Attendees agree to participate in this CME activity with full knowledge and awareness that they waive any claim they may have against the FMA for injury or other damage that may result in any way from their participation in this activity.
Please join us at the FSP 2023 Summer Pathology Conference taking place on July 14-16, 2023 at the Eau Palm Beach Resort & Spa. Exhibitors will connect with 100-150 pathologists during the conference as well as engage in over 15 hours of face to face time with attendees.
Other benefits include:
The exhibit hall is now sold out. If you would like to be added to the wait list please contact email@example.com
Thank you to the following companies for their support of the FSP 2023 Summer Pathology Conference:
Aiforia equips pathologists and scientists in preclinical, academic, and clinical labs with the most powerful deep learning artificial intelligence and cloud-based technology to increase the speed, accuracy and consistency of analyzing large and complex medical images across a variety of fields from oncology to neuroscience. Aiforia is composed of an ideal mix of scientists experienced in a variety of medical areas from pathology to cancer diagnostics, software developers who collectively hold over 100 years’ experience in artificial intelligence, and a business team with backgrounds in the pharmaceutical and biotechnology industries.
APS Medical Billing is a premier billing firm that provides expert billing and practice management solutions to pathology and laboratory practices nationwide. APS’ clients range in size from a single-physician practice to large, multi-site academic departments, reference and independent labs. The scope of our billing services and proven strategies allow APS to effectively bill for professional, technical and global components of anatomic and clinical pathology services. Please visit our website at www.apsmedbill.com.
Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.
Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of cancer patients. We target the underlying biology of cancer in Immuno-Oncology, Tumor Drivers/Resistance, DNA Damage Response and Antibody Drug Conjugates. Utilizing precision medicine and biomarker-driven indications we look to dramatically improve five-year survival. Our focus on early disease stages and relapsed patients is to 1) identify and treat patients earlier with curative intent; and 2) support relapsed and refractory patients by tackling primary or acquired resistance.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first. Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. (www.CastleTestInfo.com)
Cleveland Clinic Laboratories is a full-service, national reference laboratory dedicated to providing world-class care. Our laboratories offer high-quality, clinically impactful pathology and laboratory diagnostics services combined with readily available consultation from experienced pathologists and laboratory scientists.
Daiichi Sankyo is a pharmaceutical company focused on ADC's in lung, GI, and breast cancer.
We are pioneers in diagnostic kits for advanced DNA testing. Our goal is to eliminate tedious protocols and streamline laboratory workflows with simple, fast, and accurate genetic testing solutions. Together we can make personalized healthcare available to all patients – for a correct diagnosis and faster treatment.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
At Innovative Science Press, we are dedicated to the advacment of pathologists by producing and disseminating educational textbooks. We believe that all pathologists deserve access to quality and affordable medical training in order to help their patients. For this reason, our books are written by some of the most prominent in the field and are reasonably priced. We provide steep discounts to residents and fellows to make our products more affordable and donate frequently to the under-served countries.
Molecular diagnostic testing for indeterminate thyroid nodules utilizing multi platform testing. ThyGeNEXT is an oncogenic mutation panel that helps identify malignant thyroid nodules and ThyraMIR is a proprietary microRNA gene expression assay that helps to clarify the risk of cancer in thyroid nodules.
Specialty diagnostics at every stage of cancer care. We help you navigate the complex treatment landscape, connecting insights from patients, trials, health systems and managed care partners to power decisions that improve patient outcomes.
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
MedReceivables Advisor, LLC is a full service outsourcing medical billing company for the hospital based physician. Our company provides complete accounts receivable management services for hospital-based physicians.
Milestone's innovative products range from specimen collection, to processing, to embedding, and further, including many steps in between. Milestone's mission is to reduce patient anxiety by standardizing and expediting the pre-analytical steps of the histopathology lab and the operating room specimen collection and transportation. In doing so, our goal is to enable superior quality, same-day diagnoses. Milestone is proud to offer innovative solutions in 6 different fields: Tissue Processing, Specimen Handling, Frozen sections, Cytology, Macro Digital and Reagents. See what we have to offer: https://www.milestonemed.com
MSN's Pathology Solutions Team has over 20 years of pathology billing experience working with hospital-based practices and outreach facilities. We balance the skills and understanding of our expert billing staff with excellent technology,a combination resulting in diligent claims follow-up and collection activity for our pathology clients. MSN is passionate about client service, and we build strong partnerships with the pathology groups we serve. We are dedicated to becoming one of the leading pathology billing companies in the country.
DNA is in our blood.
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.
NeoGenomics is a Florida-based premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-certified facilities in the US and offer global capabilities with laboratories in Switzerland and Singapore.
We provide private autopsies for families looking for answers after the passing of a loved one in Natural death cases. Our pathologist is a board certified pathologist specializing in anatomic pathology. We offer a full comprehensive exam trying to find cause of death, any contributing factors as well as any underlying disease. In cases where dementia is present, we can provide confirmation of Alzheimer’s disease. We also do toxicology screening, cultures for infections present and covid swab when necessary. Our goal is to provide answers for families and closure.
Big thinking for people with rare diseases
Everything we do is driven by the needs of people who have a rare disease:
Our team believes that each person with a rare disease has the right to the best treatment.
We have nearly 30 years' experience in bringing orphan drugs to market for rare diseases, with a portfolio of 18 products and a significant research and development program.
We help to develop, and work alongside, global networks of patients, patient groups, experts, healthcare professionals, scientists, policy makers and regulators.
We employ professionals in over 30 countries, and are rapidly expanding globally.
We have unparalleled experience in the development of clinical trials for orphan drugs and in specialist regulatory requirements.
Our infrastructure has been developed to uniquely produce, package and distribute very small to high numbers of specialist products worldwide.
Recordati Rare Diseases is committed to improving the diagnosis and management of rare diseases through our educational work and the Recordati Rare Diseases Foundation.
Roche Indy is the North American headquarters of the world's largest biotech company, where more than 4,000 people work together to provide insights that help people around the world manage and improve personal health conditions. We lead the industry in the development of diagnostics products for cancer, cardiac health, infectious diseases, women's health and in diabetes management. Diagnostics informs 70 percent of clinical decisions, including the prevention, identification and treatment of diseases, and are a critical part of modern medicine as care becomes more personalized.
Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We're driven by a singular mission to make a difference for people impacted by cancer.
As an industry leader in antibody drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of our four approved medicines are built on this technology. We also focus our research efforts on novel targeted small molecule therapies. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing and commercializing life-changing medicines. We do it to help patients suffering from devastating cancers live longer, better lives.
How? We scrutinize promising molecules from every angle to unlock their full potential. We forge collaborations with industry and academic innovators to multiply the opportunities for success. And we build our company with exceptional people who press beyond “good enough” to make a profound impact. In a word, we are tenacious.
Are you with us?
The University of Miami Health System delivers leading-edge patient care by the region's best doctors, powered by the groundbreaking research and medical education of the University of Miami Leonard M. Miller School of Medicine. As South Florida's only university system, UHealth is a vital component of the community.
UHealth combines patient care, research, and education to create a front-line approach to health care. Within the UHealth system, patients can participate in clinical trials and benefit from the latest developments that are fast-tracked from the laboratory to the bedside.
FSP Member Login